Thomas Charles Caya is a notable inventor based in Somerville, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various mental health disorders.

Latest Patents

Caya holds a patent for "Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators." This patent outlines the use of these compounds as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome. He has 1 patent to his name.

Career Highlights

Caya is currently employed at Novartis AG, a leading global healthcare company. His work focuses on innovative solutions that address complex health issues, showcasing his commitment to improving patient outcomes.

Collaborations

Throughout his career, Caya has collaborated with talented professionals, including James Neef and Tejaskumar Pankajbhai Pathak. These collaborations have further enhanced his research and development efforts in the pharmaceutical industry.

Conclusion

Thomas Charles Caya is a dedicated inventor whose work in pharmaceutical compounds has the potential to make a significant impact on the treatment of various mental health disorders. His contributions to the field exemplify the importance of innovation in healthcare.

Profile summary based on public USPTO records.